SwedenBIO congratulates Amsterdam – new host city for the European Medicines Agency (EMA)

Last night, November 20, the decision was taken to locate the European Medicines Agency (EMA) in Amsterdam. This followed a tough vote to narrow down the two finalists, both of which received 13 votes during the General Affairs Council meeting in Brussels.

Sweden had hoped to host the European Medicines Agency (EMA) when it moves from London in March 2019 due to Brexit. Of the 19 countries that competed for the agency, Sweden is the second most successful country, after the UK, in receiving assignments from the EU agency.

– Of course, we are very disappointed that the EMA was not relocated to Stockholm. Locating the EU’s pharmaceutical authority here in an excellent life science environment would have been a profitable investment where EMA could have developed positively to meet the challenging needs of the future, says Jonas Ekstrand, CEO of the industry organization SwedenBIO.

But the trade association says that Amsterdam is not a bad choice either and that it is good that the issue is now settled – EMA is a very important agency where disruption of operations has serious consequences at many levels.

– Ultimately, it is about ensuring that patients have rapid access to adequate treatment. We are convinced that Amsterdam can meet these needs and we will work to ensure continued good cooperation with the authority,” continues Jonas Ekstrand.

He says that from a Swedish perspective, we need to remind ourselves that the EMA never existed here. It is not something we have lost, just something we will not get. In Sweden, we are strong on the regulatory side, and the Swedish Medicines Agency is perhaps Europe’s most respected national medicines authority. It will definitely play an even bigger role now that the British are closing shop.

– I would like to call on the Swedish government to take this opportunity to help the Director General of the Swedish Medical Products Agency, Catarina Andersson Forsman, to build on the excellence that already exists there. Why not take a Nordic perspective on the regulatory side and thus contribute to the Nordic region continuing to be a strong life science region in every sense of the word?

– I would also like to see the agency open up more to the outside world, which will benefit everyone, not least the patients who can benefit from safer and more effective new treatment methods,” concludes Jonas Ekstrand, who nevertheless sees a bright future for life science in Sweden.

For more information:

Jonas Ekstrand, CEO SwedenBIO – 070-302 08 96

The industry organization SwedenBIO’s more than 240 member companies have a total of 20,000 employees who contribute in various ways to the development of new treatments to prevent and alleviate ill health. Members include companies that are active in drug development, biotechnology, medical devices and diagnostics or are experts in areas such as business development, financing, intellectual property and law.

To the SwedenBIO press room on Mynewsdesk.